Video

Dr. O'Malley on Folate-Receptor Alpha as a Biomarker in Ovarian Cancer

David O'Malley, MD, professor, Department of Obstetrics and Gynecology, The Ohio State University Comprehensive Cancer Center, discusses folate-receptor alpha as a biomarker in ovarian cancer.

David O’Malley, MD, professor, Department of Obstetrics and Gynecology, The Ohio State University Comprehensive Cancer Center, discusses folate-receptor alpha (FRα) as a biomarker for mirvetuximab soravtansine response in the treatment of patients with ovarian cancer.

FRα is starting to pan out as a biomarker for mirvetuximab soravtansine, O’Malley says. In the phase Ib FORWARD II study presented at the 2018 ASCO Annual Meeting, researchers looked at patients with platinum-resistant ovarian cancer and divided them into subgroups based on FRα expression. Low expressers were defined as 25% to 50%, moderate expressers were 50% to 75%, and high expressers were >75%. As more experience has been gained with the use of mirvetuximab soravtansine in these patient populations, gynecologic oncologists are starting to see that the medium- and high-expressers of FRα are doing better in the progression-free and overall survival data.

O’Malley adds that while they are now focusing on the medium and high expressers, marked responses are still seen in the low expressers.

Related Videos
Lajos Pusztai, MD, DPhil
Hope S. Rugo, MD
Marc Machaalani, MD
Craig Eckfeldt, MD, PhD, assistant professor, medicine, faculty, Microbiology, Immunology, and Cancer Biology PhD Graduate Program, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Alfred L. Garfall, MD, MS
Razane El Hajj Chehade, MD
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Coral Olazagasti, MD
Barbara Jane O’Brien, MD, associate professor, Neuro-Oncology, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center